SCHEMBL3033548

SCHEMBL3033548

NC(=O)c1occc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 2/20 0.50
ALDH1A1 P00352 2/20 0.46
ADORA2A P29274 1/20 0.42
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
TSHR P16473 2/20 0.40
POLB P06746 1/20 0.40
CYP3A4 P08684 1/20 0.40
PARP1 P09874 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C19 P33261 1/20 0.40
RECQL P46063 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
FGFR1 P11362 1/20 0.40
SRC P12931 1/20 0.40
FGFR2 P21802 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549765 0.84 KMT2A (0.46) BCAT2HCRTR1HCRTR2TSHRKMT2A
SCHEMBL7796946 0.84 BACE1 (0.43) BCAT2ALDH1A1HCRTR1HCRTR2TSHR
SCHEMBL6637451 0.83 ESR1 (0.41) ALDH1A1CYP3A4MAPTCYP2C19BLM
SCHEMBL6633897 0.83 MAPK14 (0.45) ALDH1A1POLBCYP3A4MAPTCYP2C19
SCHEMBL6634313 0.81 GRM2 (0.41) ALDH1A1TSHRMAPTCYP2C19HSD17B10
SCHEMBL10434450 0.81 LMNA (0.45) ALDH1A1TSHRPOLBHSD17B10LMNA
SCHEMBL6632966 0.81 IKBKB (0.41) ALDH1A1CYP2C19HSD17B10FGFR1SRC
SCHEMBL3975038 0.81 MAPK14 (0.47) IKBKBCHUKIKBKEPKMYT1
SCHEMBL28480938 0.81 MKNK1 (0.53) ALDH1A1CYP3A4CYP2C19LMNAIKBKB
SCHEMBL7279084 0.81 SMN1; SMN2 (0.44) BCAT2ALDH1A1HCRTR1HCRTR2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116535371-B Guanidine-containing phenyl furan carboxamide compound and application thereof 华南农业大学 2025-02-18 CN claimed
CN-116535371-A Guanidine-containing phenyl furan carboxamide compound and application thereof 华南农业大学 2023-08-04 CN claimed
EP-4596548-A1 NURR1 MODULATORS Ludwig-Maximilians-Universität (DE) 2025-08-06 EP disclosed
CN-116535371-B Guanidine-containing phenyl furan carboxamide compound and application thereof 华南农业大学 2025-02-18 CN disclosed
CN-116535371-A Guanidine-containing phenyl furan carboxamide compound and application thereof 华南农业大学 2023-08-04 CN disclosed
US-9562019-B2 Substituted pyridazines as EGFR and/or KRAS inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2017-02-07 US disclosed
EP-2518063-B1 Pyridazinones and furan-containing compounds SLOAN-KETTERING INST FOR CANCER RES (US) 2017-02-01 EP disclosed
EP-2099770-B1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS SLOAN KETTERING INST CANCER (US) 2015-06-10 EP disclosed
US-20130131062-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS DJABALLAH HAKIM (US) 2013-05-23 US disclosed
EP-2518063-A1 Pyridazinones and furan-containing compounds Sloan-Kettering Institute For Cancer Research (US) 2012-10-31 EP disclosed
US-20100210649-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2010-08-19 US disclosed
EP-2099770-A2 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS Sloan-Kettering Institute for Cancer Research (US) 2009-09-16 EP disclosed
WO-2008080056-A2 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2008-07-03 WO disclosed
EP-1747214-A2 DIHYDROBENZOTHIOPHENES MERCK PATENT GmbH (DE) 2007-01-31 EP disclosed
WO-2005108355-A2 DIHYDROBENZOTHIOPHENES MERCK PATENT GMBH (DE) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131062-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS DPYD, PDXK, TYMP BCAT2 3142/4885ALDH1A1 761/4885ADORA2A 1379/4885
US-20100210649-A1 PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS DPYD, PDXK, TYMP BCAT2 3142/4885ALDH1A1 761/4885ADORA2A 1379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.